REG-4basebio Plc: Employee Long Term Incentive Plan and Issue of Equity

4BasebioAnnouncement

22/07/2025 07:02

22 July 2025

   
     


4basebio PLC

("4basebio" or the "Company")

Employee Long Term Incentive Plan and Issue of Equity

Cambridge, UK, 22 July 2025 - 4basebio PLC (AIM: 4BB), an innovation-led
provider of novel synthetic DNA products and a non-viral, thermostable nucleic
acid delivery platform announces that, pursuant to the Employees Benefit Trust
(“EBT”) operated by Fiduchi Trustees (UK) Limited, the EBT has been
awarded 29,125 ordinary shares of EUR€1.00 each in the Company (“EBT
Shares”) at £9.85 per ordinary share, being the closing mid-market price on
7 July 2025.  

As announced on 18 July 2024, the EBT was established as part of the employee
long-term incentive plan and is a discretionary trust for the benefit of
employees of the Company.

The Directors approved the issue of the EBT shares on 18 July 2025. The next
allocation is expected to take place during July 2026 and the market will be
updated at that time.

Following the settlement of the award of the EBT Shares, the EBT will hold a
total of 53,643 shares in the Company, equivalent to 0.19 per cent. of the
Company’s enlarged issued share capital.

Issue of Equity and Admission Total Voting Rights

The EBT Shares will be fully paid and will rank pari passu in all respects
with the existing ordinary shares of the Company, including, without
limitation, the right to receive all dividends and other distributions
declared, made or paid after the date of issue.

Application has been made for the EBT Shares to be admitted to trading on AIM
(“Admission”). Admission and settlement of the EBT Shares is expected to
take place at 8.00 a.m. on 23 July 2025.

Following Admission, the total number of ordinary shares in issue will be
15,538,518. The Company does not hold any ordinary shares in treasury.
Therefore, the total number of ordinary shares with voting rights will be
15,538,518. This figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct Authority's
Disclosure and Transparency Rules.

For further enquiries, please contact:

 4basebio PLC Dr. Heikki Lanckriet, CEO                                                              +44 (0)1223 967 943  
 Nominated Adviser        Cairn Financial Advisers LLP Jo Tuner / Sandy Jamieson / Ed Downes         +44 (0)20 7213 0880  
 Joint Broker RBC Capital Markets Kathryn Deegan / Matthew Coakes                                    +44 (0)20 7653 4000  
 Joint Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks                             +44 (0)20 7220 0500  

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2025 PR Newswire Association,LLC. All Rights Reserved